EVH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EVH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Evolent Health's change in receivables for the quarter that ended in Mar. 2024 was $17 Mil. It means Evolent Health's Accounts Receivable declined by $17 Mil from Dec. 2023 to Mar. 2024 .
Evolent Health's change in receivables for the fiscal year that ended in Dec. 2023 was $-170 Mil. It means Evolent Health's Accounts Receivable increased by $170 Mil from Dec. 2022 to Dec. 2023 .
Evolent Health's Accounts Receivable for the quarter that ended in Mar. 2024 was $428 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Evolent Health's Days Sales Outstanding for the three months ended in Mar. 2024 was 61.02.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Evolent Health's liquidation value for the three months ended in Mar. 2024 was $-1,110 Mil.
The historical data trend for Evolent Health's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | -16.73 | -58.42 | -24.76 | -110.67 | -170.30 |
Evolent Health Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Change In Receivables | Get a 7-Day Free Trial | 18.51 | -81.64 | -53.00 | -54.16 | 17.45 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-171 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolent Health (NYSE:EVH) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Evolent Health's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 427.739 | / | 639.653 | * | 91 |
= | 61.02 |
2. In Ben Graham's calculation of liquidation value, Evolent Health's accounts receivable are only considered to be worth 75% of book value:
Evolent Health's liquidation value for the quarter that ended in Mar. 2024 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 165.147 | - | 1595.737 | + | 0.75 * 427.739 | + | 0.5 * 0 |
= | -1,110 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Evolent Health's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Seth Blackley | officer: President | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Daniel Joseph Mccarthy | officer: PRESIDENT | 800 N GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Emily Ann Rafferty | officer: Chief Operating Officer | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Toyin Ajayi | director | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Cheryl Scott | director | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Mary Bridget Duffy | director | C/O VOCERA COMMUNICATIONS, INC., 525 RACE STREET, SAN JOSE CA 95126 |
Diane Holder | director | 800 GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Richard M Jelinek | director | 40 W 47TH STREET, FLOOR 33, NEW YORK NY 10035 |
Frank J Williams | director, officer: Chief Executive Officer | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
John Paul Johnson | officer: Chief Financial Officer | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Jonathan Weinberg | officer: General Counsel | 800 N. GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Steve Tutewohl | officer: Chief Operating Officer | 800 NORTH GLEBE ROAD, SUITE 500, ARLINGTON VA 22203 |
Tunde Sotunde | director | 800 N. GLEBE RD, SUITE 500, ARLINGTON VA 22203 |
Kim Keck | director | 30 W. MONROE STREET, SUITE 1200, CHICAGO IL 60603 |
Craig A. Barbarosh | director | 3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305 |
From GuruFocus
By PRNewswire PRNewswire • 11-29-2022
By PRNewswire PRNewswire • 07-08-2022
By PRNewswire • 08-02-2023
By GuruFocus Research GuruFocus Editor • 08-17-2022
By PRNewswire PRNewswire • 01-31-2023
By PRNewswire • 12-05-2023
By PRNewswire PRNewswire • 03-29-2023
By PRNewswire PRNewswire • 10-14-2022
By PRNewswire PRNewswire • 07-09-2022
By PRNewswire • 08-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.